US 2026/0103489 A1Published application

Epitope tags recognized by specific binders

AssigneeNANOTAG BIOTECHNOLOGIES GmbH

InventorsSteffen Frey, Hansjoerg Goetzke, Davilla Luis Felipe Opazo, Paal Erik Gustav Stenmark, Carranza Markel Martinez

Life of this patent

Estimating the term…

Abstract

The present invention provides peptides useful as epitope tags, which may be fused to a polypeptide of interest, as well as antibodies that specifically bind to these peptides. The peptides and/or antibodies can be used for detecting, immobilizing, isolating or purifying a molecule that is conjugated to such a peptide and/or antibody.

Claims20

Dependent claims

A fusion protein comprising:

(a) a peptide P comprising a sequence selected from the group consisting
(SEQ ID NO:
04)
SRLEEELRRRLTE;
(SEQ ID NO:
05)
MPSRLEEELRRRLTEP;
(SEQ ID NO:
06)
PSRLEEELRRRLTEP;
(SEQ ID NO:
07)
PSRLEEELRRRLTE;
(SEQ ID NO:
08)
GRSRLEEELRRRLTA;
(SEQ ID NO:
09)
PGSRLEEELRRRLTAP;
(SEQ ID NO:
10)
PSTRLEEELRRRLTAP;
(SEQ ID NO:
11)
SPSRLEEELRRRLTAP;
(SEQ ID NO:
12)
SPSRLEEELRRRLDAP;
(SEQ ID NO:
13)
SPSRLEEELRRRLEAP;
(SEQ ID NO:
14)
SPSRLEEELRRRLTDP;
(SEQ ID NO:
15)
SPSRLEEELRRRLTEP;
(SEQ ID NO:
16)
SPSRLEEELRRRLTADP;
(SEQ ID NO:
17)
SPSGLEEELRRRLTEP;
(SEQ ID NO:
18)
GPSRLEEELRRRLT;
(SEQ ID NO:
19)
GPSRLEEELRRRLTA;
(SEQ ID NO:
20)
GPSRLEEELRRRLTAA;
(SEQ ID NO:
21)
GPSRLEEELRRRLTAAS;
(SEQ ID NO:
22)
SPSGLEQELRRRLTAP;
(SEQ ID NO:
23)
SPSGLEQELRRRLDAP;
(SEQ ID NO:
24)
SPSGLEQELRRRLEAP;
(SEQ ID NO:
25)
SPSGLEQELRRRLTEP;
(SEQ ID NO:
26)
GPSRLEEELRRRLTAP;
(SEQ ID NO:
27)
GPSRLEEELRRRLTEP;
(SEQ ID NO:
28)
GPSRLEEELRRRLTE;
(SEQ ID NO:
29)
MSRLEEELRRRLTEP;
(SEQ ID NO:
30)
MSSRLEEELRRRLTEP;
(SEQ ID NO:
32)
GRLEEELRRRLS;
(SEQ ID NO:
33)
MSGRLEEELRRRLSP;
(SEQ ID NO:
34)
SDSGLEQELRRRLSPG;
(SEQ ID NO:
35)
PDGGLEQELRRRLTAP;
(SEQ ID NO:
36)
PSGGLEQELRRRLTAP;
(SEQ ID NO:
37)
DSPGLEQELRRRLTAP;
(SEQ ID NO:
38)
PDSGLEQELRRRLTPA;
(SEQ ID NO:
39)
SPSGLEEELRRRLTAEP;
(SEQ ID NO:
40)
GPSGLEQELRRRLT;
(SEQ ID NO:
41)
GPSGLEQELRRRLTAAS;
(SEQ ID NO:
42)
SPSRLEEELRRRLPSK;
(SEQ ID NO:
43)
SPSGLEQELRRRLTPS;
(SEQ ID NO:
44)
SPGRLEQEIRRRLSPS;
(SEQ ID NO:
45)
PSGRLEEELRRRLSPS;
(SEQ ID NO:
46)
PSGRLEEELRRRLS;
(SEQ ID NO:
47)
PSGRLEEELRRRLA;
(SEQ ID NO:
48)
PSGRLEEELRRRLSP
(SEQ ID NO:
50)
PDSGLEQELRRRLSPG;
(SEQ ID NO:
51)
PDSGLEQELRRRLTAP;
(SEQ ID NO:
52)
PSSGLEQELRRRLTAP;
(SEQ ID NO:
53)
DPSGLEQELRRRLTAP;
(SEQ ID NO:
54)
DSGPLEQELRRRLTAP;
(SEQ ID NO:
55)
SPSRLEEELRRRLTAEP;
(SEQ ID NO:
56)
SPSGLEEELRRRLTAP;
(SEQ ID NO:
57)
SPSGLEEELRRRLDAP;
(SEQ ID NO:
58)
SPSGLEEELRRRLEAP;
(SEQ ID NO:
59)
SPSGLEEELRRRLTDP;
(SEQ ID NO:
60)
SPSGLEEELRRRLTADP;
(SEQ ID NO:
169)
GPSGLEQELRRRLTA;
(SEQ ID NO:
170)
SPSGLEQELRRRLTDP;
(SEQ ID NO:
171)
SPSGLEQELRRRLTADP;
(SEQ ID NO:
172)
SPSGLEQELRRRLTAEP;
(SEQ ID NO:
173)
DSPGLEQELRRRLTAP;
(SEQ ID NO:
174)
SPSGLEQELRRRLSPS;
(SEQ ID NO:
32)
GRLEEELRRRLS;
(SEQ ID NO:
33)
MSGRLEEELRRRLSP;
(SEQ ID NO:
62)
DSGRLEEELRRRLSKG;
(SEQ ID NO:
63)
DSGRLEEELRRRLSPG;
(SEQ ID NO:
64)
SDSGLEEELRRRLSPG;
(SEQ ID NO:
65)
SDSGVEEELRRRLSPG;
(SEQ ID NO:
66)
SDSAVEEELRRRLSPG;
(SEQ ID NO:
67)
SDSGLQEELRRRLSPG;
(SEQ ID NO:
68)
SDSGLEEQLRRRLSPG;
(SEQ ID NO:
69)
SDSGLEEEIRRRLSPG;
(SEQ ID NO:
70)
SDSGLEEEVRRRLSPG;
(SEQ ID NO:
71)
DSGELEEELRRRLSPG;
(SEQ ID NO:
72)
DSGRLEQELRRRLSPG;
(SEQ ID NO:
73)
DSGRLEEEIRRRLSPG;
(SEQ ID NO:
74)
DSGRLEQEIRRRLSPG;
(SEQ ID NO:
75)
DSGRLEQEIARRLSPG;
(SEQ ID NO:
76)
DSGRLEQEIQRRLSPG;
(SEQ ID NO:
77)
DSGRLEQEIERRLSPG;
(SEQ ID NO:
78)
DSGRLEQEIRARLSPG;
(SEQ ID NO:
79)
DSGRLEQEIRQRLSPG;
(SEQ ID NO:
80)
DSGRLEQEIRERLSPG;
(SEQ ID NO:
81)
GPSRLEEELRRRL;
(SEQ ID NO:
82)
MSGLEQELRRRLTPS;
(SEQ ID NO:
83)
MSGRLEEELRRRLSPS;
(SEQ ID NO:
84)
SPSAVEEELRRRLSPS;
(SEQ ID NO:
85)
GPSAVEEELRRRLS;
(SEQ ID NO:
86)
MPSGLEQELRRRLTPS;
(SEQ ID NO:
87)
MSSGLEQELRRRLTPS;
(SEQ ID NO:
88)
MPSGRLEEELRRRLSPS;
and
(SEQ ID NO:
89)
MSGRLEEELRRRLSP;
(b) and a polypeptide.

273 more elements

Dependencies are inferred from the claim text.

Facts

Application: 19/234,249Filed 10 Jun 2025
Priority: EP 18193663.411 Sep 2018
Published: 16 Apr 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification18 codes

C07K 7/08
Linear peptides containing only normal peptide links: having 12 to 20 amino acids
C07K 16/44
Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies: against material not provided for elsewhere , e.g. haptens, metals, DNA, RNA,…
C07K 7/04
Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof: linear peptides containing only normal peptide links
C07K 14/435
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof: from animals; from humans

Family

Application17/274,755Division
Application19/234,249Division
US 12,365,705 B2Related patent
US 2022/0048947 A1Published application
US 2026/0103489 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

A fusion protein comprising:

(a) a peptide P comprising a sequence selected from the group consisting
(SEQ ID NO:
04)
SRLEEELRRRLTE;
(SEQ ID NO:
05)
MPSRLEEELRRRLTEP;
(SEQ ID NO:
06)
PSRLEEELRRRLTEP;
(SEQ ID NO:
07)
PSRLEEELRRRLTE;
(SEQ ID NO:
08)
GRSRLEEELRRRLTA;
(SEQ ID NO:
09)
PGSRLEEELRRRLTAP;
(SEQ ID NO:
10)
PSTRLEEELRRRLTAP;
(SEQ ID NO:
11)
SPSRLEEELRRRLTAP;
(SEQ ID NO:
12)
SPSRLEEELRRRLDAP;
(SEQ ID NO:
13)
SPSRLEEELRRRLEAP;
(SEQ ID NO:
14)
SPSRLEEELRRRLTDP;
(SEQ ID NO:
15)
SPSRLEEELRRRLTEP;
(SEQ ID NO:
16)
SPSRLEEELRRRLTADP;
(SEQ ID NO:
17)
SPSGLEEELRRRLTEP;
(SEQ ID NO:
18)
GPSRLEEELRRRLT;
(SEQ ID NO:
19)
GPSRLEEELRRRLTA;
(SEQ ID NO:
20)
GPSRLEEELRRRLTAA;
(SEQ ID NO:
21)
GPSRLEEELRRRLTAAS;
(SEQ ID NO:
22)
SPSGLEQELRRRLTAP;
(SEQ ID NO:
23)
SPSGLEQELRRRLDAP;
(SEQ ID NO:
24)
SPSGLEQELRRRLEAP;
(SEQ ID NO:
25)
SPSGLEQELRRRLTEP;
(SEQ ID NO:
26)
GPSRLEEELRRRLTAP;
(SEQ ID NO:
27)
GPSRLEEELRRRLTEP;
(SEQ ID NO:
28)
GPSRLEEELRRRLTE;
(SEQ ID NO:
29)
MSRLEEELRRRLTEP;
(SEQ ID NO:
30)
MSSRLEEELRRRLTEP;
(SEQ ID NO:
32)
GRLEEELRRRLS;
(SEQ ID NO:
33)
MSGRLEEELRRRLSP;
(SEQ ID NO:
34)
SDSGLEQELRRRLSPG;
(SEQ ID NO:
35)
PDGGLEQELRRRLTAP;
(SEQ ID NO:
36)
PSGGLEQELRRRLTAP;
(SEQ ID NO:
37)
DSPGLEQELRRRLTAP;
(SEQ ID NO:
38)
PDSGLEQELRRRLTPA;
(SEQ ID NO:
39)
SPSGLEEELRRRLTAEP;
(SEQ ID NO:
40)
GPSGLEQELRRRLT;
(SEQ ID NO:
41)
GPSGLEQELRRRLTAAS;
(SEQ ID NO:
42)
SPSRLEEELRRRLPSK;
(SEQ ID NO:
43)
SPSGLEQELRRRLTPS;
(SEQ ID NO:
44)
SPGRLEQEIRRRLSPS;
(SEQ ID NO:
45)
PSGRLEEELRRRLSPS;
(SEQ ID NO:
46)
PSGRLEEELRRRLS;
(SEQ ID NO:
47)
PSGRLEEELRRRLA;
(SEQ ID NO:
48)
PSGRLEEELRRRLSP
(SEQ ID NO:
50)
PDSGLEQELRRRLSPG;
(SEQ ID NO:
51)
PDSGLEQELRRRLTAP;
(SEQ ID NO:
52)
PSSGLEQELRRRLTAP;
(SEQ ID NO:
53)
DPSGLEQELRRRLTAP;
(SEQ ID NO:
54)
DSGPLEQELRRRLTAP;
(SEQ ID NO:
55)
SPSRLEEELRRRLTAEP;
(SEQ ID NO:
56)
SPSGLEEELRRRLTAP;
(SEQ ID NO:
57)
SPSGLEEELRRRLDAP;
(SEQ ID NO:
58)
SPSGLEEELRRRLEAP;
(SEQ ID NO:
59)
SPSGLEEELRRRLTDP;
(SEQ ID NO:
60)
SPSGLEEELRRRLTADP;
(SEQ ID NO:
169)
GPSGLEQELRRRLTA;
(SEQ ID NO:
170)
SPSGLEQELRRRLTDP;
(SEQ ID NO:
171)
SPSGLEQELRRRLTADP;
(SEQ ID NO:
172)
SPSGLEQELRRRLTAEP;
(SEQ ID NO:
173)
DSPGLEQELRRRLTAP;
(SEQ ID NO:
174)
SPSGLEQELRRRLSPS;
(SEQ ID NO:
32)
GRLEEELRRRLS;
(SEQ ID NO:
33)
MSGRLEEELRRRLSP;
(SEQ ID NO:
62)
DSGRLEEELRRRLSKG;
(SEQ ID NO:
63)
DSGRLEEELRRRLSPG;
(SEQ ID NO:
64)
SDSGLEEELRRRLSPG;
(SEQ ID NO:
65)
SDSGVEEELRRRLSPG;
(SEQ ID NO:
66)
SDSAVEEELRRRLSPG;
(SEQ ID NO:
67)
SDSGLQEELRRRLSPG;
(SEQ ID NO:
68)
SDSGLEEQLRRRLSPG;
(SEQ ID NO:
69)
SDSGLEEEIRRRLSPG;
(SEQ ID NO:
70)
SDSGLEEEVRRRLSPG;
(SEQ ID NO:
71)
DSGELEEELRRRLSPG;
(SEQ ID NO:
72)
DSGRLEQELRRRLSPG;
(SEQ ID NO:
73)
DSGRLEEEIRRRLSPG;
(SEQ ID NO:
74)
DSGRLEQEIRRRLSPG;
(SEQ ID NO:
75)
DSGRLEQEIARRLSPG;
(SEQ ID NO:
76)
DSGRLEQEIQRRLSPG;
(SEQ ID NO:
77)
DSGRLEQEIERRLSPG;
(SEQ ID NO:
78)
DSGRLEQEIRARLSPG;
(SEQ ID NO:
79)
DSGRLEQEIRQRLSPG;
(SEQ ID NO:
80)
DSGRLEQEIRERLSPG;
(SEQ ID NO:
81)
GPSRLEEELRRRL;
(SEQ ID NO:
82)
MSGLEQELRRRLTPS;
(SEQ ID NO:
83)
MSGRLEEELRRRLSPS;
(SEQ ID NO:
84)
SPSAVEEELRRRLSPS;
(SEQ ID NO:
85)
GPSAVEEELRRRLS;
(SEQ ID NO:
86)
MPSGLEQELRRRLTPS;
(SEQ ID NO:
87)
MSSGLEQELRRRLTPS;
(SEQ ID NO:
88)
MPSGRLEEELRRRLSPS;
and
(SEQ ID NO:
89)
MSGRLEEELRRRLSP;
(b) and a polypeptide.

273 more elements

Facts

Application

19/234,249Filed 10 Jun 2025

Priority

EP 18193663.411 Sep 2018

Published

16 Apr 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification18 codes

C07K 7/08
Linear peptides containing only normal peptide links: having 12 to 20 amino acids
C07K 16/44
Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies: against material not provided for elsewhere , e.g. haptens, metals, DNA, RNA,…
C07K 7/04
Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof: linear peptides containing only normal peptide links
C07K 14/435
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof: from animals; from humans